Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Ekso Bionics Holdings Inc is a medical instruments & supplies business based in the US. Ekso Bionics shares (EKSO) are listed on the NASDAQ and all prices are listed in US Dollars. Ekso Bionics employs 39 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $2.42 |
|---|---|
| 52-week range | $2.20 - $14.98 |
| 50-day moving average | $3.03 |
| 200-day moving average | $4.45 |
| Wall St. target price | $11.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.01 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.42 from 2022-01-26
| 1 week (2022-01-21) | 2.42 |
|---|---|
| 1 month (2021-12-28) | -10.04% |
| 3 months (2021-10-28) | -38.89% |
| 6 months (2021-07-28) | -50.31% |
| 1 year (2021-01-28) | -73.98% |
|---|---|
| 2 years (2020-01-28) | 494.30% |
| 3 years (2019-01-28) | 46.67% |
| 5 years (2017-01-27) | 4.12 |
| Revenue TTM | $9.4 million |
|---|---|
| Gross profit TTM | $5.1 million |
| Return on assets TTM | -20.67% |
| Return on equity TTM | -45.83% |
| Profit margin | -115.42% |
| Book value | $3.08 |
| Market capitalisation | $30.8 million |
TTM: trailing 12 months
We're not expecting Ekso Bionics to pay a dividend over the next 12 months.
Ekso Bionics's shares were split on a 1:15 basis on 24 March 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ekso Bionics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Ekso Bionics shares which in turn could have impacted Ekso Bionics's share price.
Over the last 12 months, Ekso Bionics's shares have ranged in value from as little as $2.202 up to $14.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ekso Bionics's is 1.9002. This would suggest that Ekso Bionics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the United States and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, sells, and rents exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, sells, and rents exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation and OttoBock Healthcare Product GmbH.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.